Stay updated with breaking news from Chris Senner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “Annual...
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Vaishnavi, and I'll be your operator for today.
EXEL earnings call for the period ending December 31, 2022.
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...
EXEL earnings call for the period ending June 30, 2022.